Upcoming AWS Coverage on Juno Therapeutics Post-Earnings Results

LONDON, UK / ACCESSWIRE / May 11, 2017 / Active Wall St. blog coverage looks at the headline from Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) as the Company announced on May 10, 2017, that the Company plans to initiate a Phase 2 clinical trial, targeting a specific genetic subset of patients identified by a responder analysis of the SAGA trial. The Company also revealed financial results for the quarter ended March 31, 2017. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Aevi Genomic Medicine's competitors within the Biotechnology space, Juno Therapeutics, Inc. (NASDAQ: JUNO), reported on May 04, 2017, its financial results and business highlights for Q1 2017. AWS will be initiating a research report on Juno Therapeutics in the coming days.

Today, AWS is promoting its blog coverage on GNMX; touching on JUNO. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

The Phase 2 Trial

In H2 2017, Aevi Genomics plans to initiate a Phase 2 trial of AEVI-001 in a smaller genetic subset to confirm genetic responders. The Company believed that the data will help determine a clear path to market approval and are expected by mid-2018. Meanwhile apart from the AEVI-001 studies that are currently planned for this year, Aevi Genomics remains on track to initiate the Phase 1/2 signal finding study of AEVI-002, the Anti-LIGHT antibody (Anti-LIGHT mAb) in Severe Pediatric Onset Crohn's Disease in collaboration with CHOP with initial data anticipated in H2 2017. Patient recruitment for AEVI-002 in Severe Pediatric Onset Crohn's Disease to begin during 2Q 2017

Aevi Genomics stated that in an ad-hoc analysis of data found in the recently completed SAGA trial, 89% of the patients within the 9-Gene subset achieved a clinical response on ADHD-RS and 72% achieved a clinical response on CGI-I. Further analysis of this data revealed a single gene, contactin-4 (CNTN4), that was highly enriched in the responder population and makes up for approximately 5% of the pediatric ADHD population. These patients had a 100% response rate on ADHD-RS and 83% response rate on CGI-I to AEVI-001 in the SAGA trial.

"Following additional analysis of the SAGA trial, we remain positive about the genetic subset of patients identified that demonstrate a clear and statistically significant response to AEVI-001," said Mike Cola, CEO of Aevi Genomic Medicine, "This discovery will allow us to move forward with the development of AEVI-001 in ADHD, and potentially other neurodevelopmental disorders in the future, including Autism Spectrum Disorder. We look forward to initiating the Phase 2 trial of AEVI-001 in patients with the identified genetic subset during the second half of 2017 and anticipate announcing top-line data in mid-2018."

Financial Results

For the quarter ended March 31, 2017 Aevi Genomics reported a net loss of $10.92 million, or $0.29 per share, compared with a net loss of $11.14 million, or $0.34 per share, for Q1 2016.

For Q1 2017, Aevi Genomics reported research and development expenses of $7.95 million, increasing from $6.95 million for the same period in 2016 mainly due to increased cost associated with the clinical advancement of AEVI-001 and AEVI-002.

Aevi Genomics' cash and cash equivalents as of March 31, 2017 were $29.20 million compared to $39.84 million as of December 31, 2016. The Company expects its reported cash balance to fund operations through the end of Q2 2018.

Stock Performance

At the close of trading session on Wednesday, May 10, 2017, following the announcement, Aevi Genomic Medicine's stock price dropped 9.04% to end the day at $1.51. A total volume of 490.18 thousand shares were exchanged during the session. The stock currently has a market cap of $56.07 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street